CENEXI
Gland Pharma Q4 Results: Net profit more than doubles to Rs 192.4 crore
The company declared its first-ever post-listing dividend of Rs 20 per equity share for FY24.
Gland Pharma Q4 Results: Firm misses profit view on higher employee costs
Indian generic injectables maker Gland Pharma reported fourth-quarter profit below estimates on Wednesday, as soaring employee expenses outweighed strong demand in its core markets.
Gland Pharma shares fall 6% as ex-promoter likely sells stake in block deals
Shares of Gland Pharma dropped 6% to Rs 1,745 on BSE as entities related to ex-promoter Dr Ravi Penmetsa sold 5.5% equity. Large block deals of 91 lakh shares worth Rs 1,600 crore reported.
Hot Stocks: Brokerage views on Gland Pharma, Bharat Forge, M&M and CG Consumer
Morgan Stanley maintained an Equal Weight rating on Crompton Greaves Consumer and an overweight rating on Bharat Forge. Jefferies recommended a hold rating on M&M and BofA Securities recommended a buy on Gland Pharma.
Gland Pharma shares climb over 6% post Q2 results. Should you buy or sell?
Meanwhile, the company's earnings before interest, taxes, depreciation and amortization (EBITDA) came in at Rs 320.5 crore, up from Rs 297 crore in the year-ago period.
Gland Pharma surges 20% as biz momentum seen turning
A better pricing environment in the US, impending product launches, and prospects of superior profitability are also seen boosting the earnings of the company going ahead, analysts said.
- Go To Page 1
Sensex slips 107 pts dragged by FMCG, metal stocks in run up to key data, RBI policy
From the Sensex pack, Power Grid, M&M, JSW Steel, Sun Pharma, Nestle and Relaince Industries closed in the red. The market breadth was skewed in the favour of the bulls. About 1,853 stocks gained, 1,751 declined, and 151 remained unchanged on the BSE.
Gland Pharma shares zoom 20% as Q1 growth triggers upgrades
Global brokerage firm Jefferies upgraded Gland Pharma's stock to buy from underperform with an increased price target of Rs 1,640 from Rs 1,065 earlier. Bernstein also gave an outperform rating on Gland Pharma, saying that the Q1 numbers point towards early signs of revival in base business.
Sensex opens flat tracking mixed global cues; Nifty above 19,600
The BSE Sensex was trading 22 points or 0.03% higher at 65,976. Nifty50 was trading at 19,604, up 7 points or 0.04% at around 9.23 am.
Gland Pharma shares hit 20% lower circuit after disappointing Q4 results
Gland Pharma's stock prices hit a 20% lower circuit on BSE after the firm reported a 72% YoY drop in net profit to Rs 79 crore in Q4FY23 due to a production shutdown at one of its facilities in Telangana and soft demand. The company had posted a net profit of Rs 285 crore in the same quarter of the previous year. Its revenue from operations slumped 29% YoY to Rs 785 crore in Q4FY23.
Gland Pharma net profit down 72% to Rs 79 crore in Q4FY23
Gland Pharma on Thursday reported 72% year-on-year (YoY) drop in net profit to Rs 79 crores in Q4FY23 due to production shutdown at one of its facilities in Telangana and soft demand. The company reported net profit of Rs 285 crores in the same quarter of the previous year.Revenue from operations slumped 29% YoY in Q4FY23 to Rs 785 crore in Q4FY23.
Buy Gland Pharma, target price Rs 1700: Motilal Oswal Financial Services
Gland Pharma, incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 22233.18 Crore) operating in Pharmaceuticals sector.
Adani Group firms dominate list of top wealth creators in 2022; Paytm, Zomato bleed most
From being the country’s biggest IPO, Paytm ended up being the biggest wealth destroyer over the past year. Amidst net losses, investors have increasingly shown discomfort over the complicated business model of the financial services company.
Fosun taps big buyout funds for Gland Pharma
Buyout firms Advent International, Baring Private Equity Asia (now owned by EQT), Bain Capital, Blackstone, Carlyle and KKR are among those who have been approached to buy the Fosun-owned Gland Pharma, in what would be one of the largest pharma deals in the country, said multiple people aware of developments.
Hot Stocks: Gland Pharma, Mirza International and Agro Tech Foods could give 19-30% return
Offices and schools have opened, which creates an incremental demand for shoes and that benefits the shoe manufacturers, the brokerage said. After growing in metro cities, management has now shifted its focus to tier 2 & 3 cities where management sensed larger growth opportunities.
Gland Pharma falls 5% after announcing Cenexi Group acquisition
Cenexi, along with its subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill finished drugs, including capabilities on oncology and complex products. It has presence across four manufacturing sites in Europe which include three sites in France and one site in Belgium.
Buy Gland Pharma, target price Rs 2470: Motilal Oswal Financial Services
Gland Pharma, incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 30927.66 Crore) operating in Pharmaceuticals sector.
Stocks in the news: Wipro, Britannia, Cipla, IDFC, Biocon and Gland Pharma
BNP Paribas Arbitrage offloaded over 18,00,164 lakh shares at an average price of Rs 405 apiece of IT major Wipro for Rs 72.9 crore through an open market transaction.
Gland Pharma acquires French CDMO Cenexi for €120 million
Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of CDMO of pharmaceutical products with expertise in sterile liquid and lyophilized fillfinished drug, including capabilities on oncology and complex products, with revenue for CY21 stood at Euro 184.1 million.
Load More
